Immunocore adds $40M from Gates Foundation

T cell receptor (TCR) company Immunocore Ltd. (Abingdon, U.K.) received a $40 million equity investment from the Bill & Melinda Gates Foundation as part of a collaboration to develop new therapies to treat infectious diseases.

Immunocore said the new capital will be used to accelerate the development of the biotech's two infectious disease platforms: immune mobilizing monoclonal TCRs against virus (ImmTAV) and immune mobilizing monoclonal TCRs against bacteria (ImmTAB). ...